Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment

V Kunzmann; T Ruediger; M Hallek; HK Mueller-Hermelink; Martin Wilhelm

doi:10.1182/blood.V98.6.1991

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment

V Kunzmann, T Ruediger, M Hallek, HK Mueller-Hermelink, Martin Wilhelm^* (Last author)

^*Corresponding author for this work

Research output: Contribution to journal › Letter to the editor › peer-review

18 Citations (Web of Science)

Original language	English
Pages (from-to)	1991-1992
Journal	BLOOD
Volume	98
Issue number	6
DOIs	https://doi.org/10.1182/blood.V98.6.1991
Publication status	Published - 2001

Keywords

CHRONIC LYMPHOCYTIC-LEUKEMIA
LEUKOSTASIS

Access to Document

10.1182/blood.V98.6.1991

Cite this

Kunzmann, V., Ruediger, T., Hallek, M., Mueller-Hermelink, HK., & Wilhelm, M. (2001). Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. BLOOD , 98(6), 1991-1992. https://doi.org/10.1182/blood.V98.6.1991

Kunzmann, V ; Ruediger, T ; Hallek, M et al. / Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. In: BLOOD 2001 ; Vol. 98, No. 6. pp. 1991-1992.

@article{f0ea666bdb544116b3babf004bc6f63b,

title = "Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment",

keywords = "CHRONIC LYMPHOCYTIC-LEUKEMIA, LEUKOSTASIS",

author = "V Kunzmann and T Ruediger and M Hallek and HK Mueller-Hermelink and Martin Wilhelm",

year = "2001",

doi = "10.1182/blood.V98.6.1991",

language = "English",

volume = "98",

pages = "1991--1992",

journal = "BLOOD ",

issn = "0006-4971",

publisher = "American Society of Hematology ",

number = "6",

}

Kunzmann, V, Ruediger, T, Hallek, M, Mueller-Hermelink, HK & Wilhelm, M 2001, 'Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment', BLOOD , vol. 98, no. 6, pp. 1991-1992. https://doi.org/10.1182/blood.V98.6.1991

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. / Kunzmann, V; Ruediger, T; Hallek, M et al.
In: BLOOD , Vol. 98, No. 6, 2001, p. 1991-1992.

Research output: Contribution to journal › Letter to the editor › peer-review

TY - JOUR

T1 - Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment

AU - Kunzmann, V

AU - Ruediger, T

AU - Hallek, M

AU - Mueller-Hermelink, HK

AU - Wilhelm, Martin

PY - 2001

Y1 - 2001

KW - CHRONIC LYMPHOCYTIC-LEUKEMIA

KW - LEUKOSTASIS

U2 - 10.1182/blood.V98.6.1991

DO - 10.1182/blood.V98.6.1991

M3 - Letter to the editor

C2 - 11565541

SN - 0006-4971

VL - 98

SP - 1991

EP - 1992

JO - BLOOD

JF - BLOOD

IS - 6

ER -

Kunzmann V, Ruediger T, Hallek M, Mueller-Hermelink HK, Wilhelm M. Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. BLOOD . 2001;98(6):1991-1992. doi: 10.1182/blood.V98.6.1991